Incidence and risk factors for acquired colonization and infection due to extended-spectrum beta-lactamase-producing Gram-negative bacilli: a retrospective analysis in three ICUs with low multidrug resistance rate.
Aged
Anti-Bacterial Agents
/ therapeutic use
Carbapenems
/ therapeutic use
Cross Infection
/ epidemiology
Drug Resistance, Multiple, Bacterial
Female
France
/ epidemiology
Gram-Negative Bacteria
/ drug effects
Gram-Negative Bacterial Infections
/ epidemiology
Humans
Incidence
Intensive Care Units
Male
Middle Aged
Predictive Value of Tests
Prevalence
Retrospective Studies
Risk Factors
beta-Lactamases
Bacteremia
Decontamination
Extended-spectrum beta-lactamase-producing Enterobacteriaceae
Gram-negative bacteria
Healthcare-associated pneumonia
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
22
10
2019
accepted:
17
12
2019
pubmed:
4
1
2020
medline:
15
12
2020
entrez:
4
1
2020
Statut:
ppublish
Résumé
The purpose of this study is to assess risk factors for the acquisition of extended-spectrum β-lactamase-producing Gram-negative bacilli (ESBL-GNB) colonization and infection (AI) in ICUs with low ESBL-GNB prevalence rate. We conducted a retrospective observational study in three ICUs in Bretagne, France. All patients admitted from January 2016 to September 2017 with a length of stay of 2 days or more were included. Universal screening for ESBL-GNB colonization was performed in all participating ICUs. Of the 3250 included patients, 131 (4.0%) were colonized at admission, 59 acquired colonization while hospitalized (1.9%; 95% CI [1.5-2.5%]), and 15 (0.5%; 95% CI [0.3-0.8%]) acquired ESBL-GNB infections. In the case of infection, the specificity and the negative predictive values of preexistent colonization for the ESBL-GNB etiology were 93.2% [91.5-95.1%] and 95.2% [93.5-97.1%], respectively. Colonization was the main risk factor for ESBL-GNB AI (OR = 9.61; 95% CI [2.86-32.29]; p < 0.001). Antimicrobial susceptibility of non-ESBL-GNB isolates responsible for AI was similar for any non-carbapenem β-lactam (95%) and imipenem (94%). ESBL-GNB AIs were rare in ICUs with low ESBL-GNB prevalence rate. Prior colonization was the main risk factor for subsequent infection. Empirical carbapenem therapy could be avoided in non ESBL-GNB colonized patients with suspected AI.
Identifiants
pubmed: 31898797
doi: 10.1007/s10096-019-03800-y
pii: 10.1007/s10096-019-03800-y
pmc: PMC7222057
doi:
Substances chimiques
Anti-Bacterial Agents
0
Carbapenems
0
beta-Lactamases
EC 3.5.2.6
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
889-895Références
Medicine (Baltimore). 2014 Oct;93(17):298-309
pubmed: 25398065
Crit Care Med. 2014 May;42(5):1121-30
pubmed: 24365857
Lancet Infect Dis. 2013 Aug;13(8):665-71
pubmed: 23622939
Microb Drug Resist. 2006 Spring;12(1):50-8
pubmed: 16584309
J Infect. 2016 Sep;73(3):200-9
pubmed: 27373765
PLoS One. 2018 Aug 8;13(8):e0201688
pubmed: 30089150
Antimicrob Agents Chemother. 2006 Feb;50(2):498-504
pubmed: 16436702
Crit Care Med. 2016 Apr;44(4):699-706
pubmed: 26571186
Clin Microbiol Rev. 2001 Oct;14(4):933-51, table of contents
pubmed: 11585791
Intensive Care Med. 2018 May;44(5):616-626
pubmed: 29663045
Clin Infect Dis. 2012 Dec;55(11):1505-11
pubmed: 22955436
Ann Intensive Care. 2017 Dec;7(1):61
pubmed: 28608133
Crit Care Med. 2017 Apr;45(4):705-714
pubmed: 28157141
J Hosp Infect. 2013 Aug;84(4):294-9
pubmed: 23846237
Eur Respir J. 2017 Sep 10;50(3):
pubmed: 28890434
J Antimicrob Chemother. 2016 Apr;71(4):1088-97
pubmed: 26755492
Crit Care. 2011;15(2):R100
pubmed: 21418635
Am J Infect Control. 2012 Nov;40(9):845-8
pubmed: 22325483
Infect Control Hosp Epidemiol. 2005 Feb;26(2):161-5
pubmed: 15756887
Clin Infect Dis. 2007 Nov 15;45(10):1347-50
pubmed: 17968833
Antimicrob Resist Infect Control. 2019 Jul 10;8:112
pubmed: 31333839
Am J Infect Control. 1988 Jun;16(3):128-40
pubmed: 2841893
Clin Infect Dis. 2018 Feb 1;66(4):497-503
pubmed: 29186403
Clin Microbiol Rev. 2005 Oct;18(4):657-86
pubmed: 16223952
Clin Microbiol Infect. 2020 Apr;26(4):485-491
pubmed: 31421272
Am J Infect Control. 2012 Jun;40(5):396-407
pubmed: 21908073
Intensive Care Med. 2012 Dec;38(12):1930-45
pubmed: 23011531
Clin Microbiol Infect. 2018 Apr;24(4):429.e7-429.e12
pubmed: 28962997